Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations

Abhay Singh, Akriti Jain, Sophia Balderman, Sujata Patil, Anjali Advani, Moaath Mustafa Ali, John Molina, Taylor Lucas, Tracy Cinalli, Ramandeep Mann, Lucy McCahon, Sudipto Mukherjee, Aaron Gerds, Yogen Saunthararajah, Jaroslaw Maciejewski, Hetty Carraway, Babal Jha, Alex Adjei

Blood (2025) 146 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2025-2096

Published: 2025

Journal Articles

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Marina Kremyanskaya, Aaron Gerds, Rupali Bhave, Andrew Kuykendall, Eunice Wang, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Kathryn Johnson, Ashley Yu, Anna Rita Migliaccio, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2025-3829

Published: 2025

Journal Articles

Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study

Ali Mushtaq, Omer Ashruf, Larry Cripe, Abhay Singh, John Molina, Hetty Carraway, Sudipto Mukherjee, Aaron Gerds, Akriti Jain

Blood (2025) 146 (Supplement 1): 3826.

https://doi.org/10.1182/blood-2025-3826

Published: 2025

Journal Articles

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Naveen Pemmaraju, Andrew Kuykendall, Ellen Ritchie, Jason Gotlib, Jeanne Palmer, Aaron Gerds, David Oubre, Prof. Uttam Kumar Nath, Gregory Vosganian, Suneel Gupta, Pedro Oyuela, Sarita Khanna, Arturo Molina, Marina Kremyanskaya

Blood (2025) 146 (Supplement 1): 3810.

https://doi.org/10.1182/blood-2025-3810

Published: 2025

Journal Articles

Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study

Debolina Pramanik, Yanwen Chen, Shramana Sarkar, Aaron Gerds, Hetty Carraway, Abhay Singh, Anjali Advani, Moaath Mustafa Ali, John Molina, Sophia Balderman, Akriti Jain, Faiz Anwer, Sudipto Mukherjee

Blood (2025) 146 (Supplement 1): 3790.

https://doi.org/10.1182/blood-2025-3790

Published: 2025

Journal Articles

Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis

Debolina Pramanik, Yanwen Chen, Shramana Sarkar, Ishan Gupta, Aaron Gerds, Hetty Carraway, Abhay Singh, Anjali Advani, Moaath Mustafa Ali, John Molina, Sophia Balderman, Akriti Jain, Faiz Anwer, Sudipto Mukherjee

Blood (2025) 146 (Supplement 1): 3772.

https://doi.org/10.1182/blood-2025-3772

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Jeanne Palmer, Jonathan How, Prithviraj Bose, Pankit Vachhani, Adam Mead, Jonathan Sillar, Aaron Gerds, Angela Fleischman, Caitlin O'Neill, Ross Baker, Ronald Hoffman, Shiangtung Jung, Jon Ruckle, Keyvan Yousefi, Sanjay Bhanot, Terry Barrett, Ruben Mesa

Blood (2025) 146 (Supplement 1): 82.

https://doi.org/10.1182/blood-2025-82

Published: 2025

Journal Articles

Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022

Husayn Ladha, Hetty Carraway, Aaron Gerds, Abhay Singh, Anjali Advani, Moaath Mustafa Ali, John Molina, Sophia Balderman, Akriti Jain, Faiz Anwer, Sudipto Mukherjee

Blood (2025) 146 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2025-4497

Published: 2025

Journal Articles

Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States

Aaron Gerds, Angela (Qi) Fan, Michelle Jerry, Alicia Cerretani, Anh Thu Tran, Luis Hernandez

Blood (2025) 146 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2025-2854

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort

Blood (2025) 146 (Supplement 1): 5185.

https://doi.org/10.1182/blood-2025-5185

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Chi-Joan How, Gabriela Hobbs, Aaron Gerds, Andriy Derkach, Emily Burton, Aurora Duran, Katherine Kan, Michael Mauro, Brian Chernak, Tamanna Haque, Raajit Rampal

Blood (2025) 146 (Supplement 1): 5606.

https://doi.org/10.1182/blood-2025-5606

Published: 2025

Journal Articles

Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis

Blood (2025) 146 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2025-6712

Published: 2025

Journal Articles

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Andrew Kuykendall, Francesca Palandri, Bella Vo, Fulya Sen Nikitas, Nicholas Meader, Shiyuan Zhang, Tom (sizhu) Liu, Shuang Wang, Gautam Sajeev, Mirko Fillbrunn, James Signorovitch, Jasmine Sahni, Dwaipayan Patnaik, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2025-2031

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose, Elizabeth Hexner, Laura Michaelis, Aaron Gerds, Akriti Jain, Prioty Islam, Raajit Rampal, Ronan Swords, Moshe Talpaz, Kristen Pettit, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Anna Halpern

Blood (2025) 146 (Supplement 1): 2042.

https://doi.org/10.1182/blood-2025-2042

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study

Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022

Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only